Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2027.

## Plain-English Summary

This bill would place a limit on how much people with diabetes have to pay out-of-pocket for the supplies they need to manage their condition. Starting January 1, 2027, insurance plans would not be allowed to charge more than $25 for a 30-day supply of equipment and supplies used to take insulin or monitor blood sugar levels — things like insulin pens, syringes, lancets, and continuous glucose monitors. For devices designed to last longer than 30 days, insurance companies would not be permitted to charge a deductible at all.

The bill would affect Rhode Islanders who rely on insulin or need to regularly monitor their blood glucose, which primarily includes people living with Type 1 or Type 2 diabetes. It would also apply to insurance companies offering accident and sickness insurance policies in Rhode Island, requiring them to adjust how they structure cost-sharing for these specific diabetes-related supplies.

Currently, the cost of diabetes management supplies can be a significant financial burden for patients, especially those with high-deductible health plans. This bill aims to reduce that burden by capping costs regardless of a person's insurance plan design. It is worth noting that the bill is still in early stages — it has been referred to the House Health & Human Services Committee and recommended to be held for further study, meaning it has not yet been passed into law.